A highly potent small molecule BMP inhibitor; inhibiting BMP type I receptors ALK2 (IC50: 5 nM), ALK3 (IC50: 30 nM) and ALK6 (TGFβ1/BMP signaling) and subsequent SMAD phosphorylation; useful tool in stem cell biology. LDN 193189 shows significant in vivo clinical utility, inhibiting FOP and ectopic ossification and a potential agent in the treatment of NSCLC lung tumors.

*Promotion: LDN 193189 HCl is also part of Inhibitor Set(s):

Prime Source Information:
The molecule of LDN 193189 contains multiple basic nitrogens, which could form 1-4 eq HCl salt of LDN 193189. This ligand from Axon is the best quality drug standard and its accurate salt form has been determined by microanalysis and specified on the certificate of analysis (COA) of every batch.

KEYWORDS: LDN 193189 hydrochloride | supplier | BMP inhibitor | DM 3189 HCl | LDN193189 | DM3189 | CAS [1435934-00-1] | [1062368-24-4] | [1062368-62-0] | TGF-β | BMP-ALK | Antagonist | RSTK | ALK2 | ALK3 | ALK6 | SMAD | stem cell biology | FOP | ectopic ossification | NSCLC